User:Karisma Moll/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
[https://www.sciencedirect.com/science/article/pii/S0304416520301483#t0005 Proline Peptidase Overview] | [https://www.sciencedirect.com/science/article/pii/S0304416520301483#t0005 Proline Peptidase Overview] | ||
=== History === | === History === | ||
| - | Dipeptidyl Peptidase IV's role in the inactivation of [https://en.wikipedia.org/wiki/Incretin incretin hormones] was discovered in the 1990s. Animal studies were conducted in the late 1990s, followed by human studies in the early 2000s. The first DPPIV inhibitors (sitagliptin, vildagliptin, alogliptin, saxagliptin, and linagliptin) were approved starting in 2006, and now serve as monotherapy or add-on to other therapies in a glucose-lowering capacity. <ref name="Ahrén">PMID:31275243</ref> Since their approval, there have been multiple long-term trials to continue exploring the long-term effects of these medications. It is known that gliptins directly impact the pancreas, kidney, heart, and vessels. The most investigated thus far is the effects of gliptins on | + | Dipeptidyl Peptidase IV's role in the inactivation of [https://en.wikipedia.org/wiki/Incretin incretin hormones] was discovered in the 1990s. Animal studies were conducted in the late 1990s, followed by human studies in the early 2000s. The first DPPIV inhibitors (sitagliptin, vildagliptin, alogliptin, saxagliptin, and linagliptin) were approved starting in 2006, and now serve as monotherapy or add-on to other therapies in a glucose-lowering capacity. <ref name="Ahrén">PMID:31275243</ref> Since their approval, there have been multiple long-term trials to continue exploring the long-term effects of these medications. It is known that gliptins directly impact the pancreas, kidney, heart, and vessels. The most investigated thus far is the effects of gliptins on real and cardiovascular functioning. <ref name="Khalse">PMID:30294582</ref> Results of phase II and III trails indicated that gliptins did not harm the cardiovascular system. A meta-analysis implicated two possible beneficial effects for patients treated with these medications: a reduction in cardiovascular effects and a direct renoprotective effect. <ref name="Hocher">PMID:22947920</ref> |
| - | Results of phase II and III | + | |
=== Function === | === Function === | ||
Revision as of 14:26, 2 April 2024
DPPIV in Humans
| |||||||||||
References
- ↑ Ahrén B. DPP-4 Inhibition and the Path to Clinical Proof. Front Endocrinol (Lausanne). 2019 Jun 19;10:376. PMID:31275243 doi:10.3389/fendo.2019.00376
- ↑ Khalse M, Bhargava A. A Review on Cardiovascular Outcome Studies of Dipeptidyl Peptidase-4 Inhibitors. Indian J Endocrinol Metab. 2018 Sep-Oct;22(5):689-695. PMID:30294582 doi:10.4103/ijem.IJEM_104_18
- ↑ Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research. Kidney Blood Press Res. 2012;36(1):65-84. PMID:22947920 doi:10.1159/000339028
- ↑ 4.0 4.1 Hiramatsu H, Kyono K, Higashiyama Y, Fukushima C, Shima H, Sugiyama S, Inaka K, Yamamoto A, Shimizu R. The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed beta-propeller fold. Biochem Biophys Res Commun. 2003 Mar 21;302(4):849-54. PMID:12646248
Student Contributors
- Karisma Moll
- Merritt Jugo
- Sam Magnabosco
